An update on current treatment strategies for managing bronchiolitis obliterans syndrome after lung transplantation

References

• Chambers DC, Cherikh WS, Goldfarb SB, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018 Oct;37(10):1169–1183.
   PubMedGoogle Scholar
• Yusen RD, Edwards LB, Dipchand AI, et al. The registry of the international society for heart and lung transplantation: thirty-third adult lung and heart-lung transplant report-2016; Focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016 Oct;35(10):1170–1184.
   PubMed Web of Science ®Google Scholar
• Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019 May;38(5):493–503.
   PubMed Web of Science ®Google Scholar
• Kotecha S, Paraskeva MA, Levin K, et al. An update on chronic lung allograft dysfunction. Ann Transl Med. 2020 Mar;8(6):417.
   PubMed Web of Science ®Google Scholar
• Sato M. Bronchiolitis obliterans syndrome and restrictive allograft syndrome after lung transplantation: why are there two distinct forms of chronic lung allograft dysfunction? Ann Transl Med. 2020 Mar;8(6):418.
   PubMed Web of Science ®Google Scholar
• Tian D, Huang H, Wen HY. Noninvasive methods for detection of chronic lung allograft dysfunction in lung transplantation. Transplant Rev (Orlando). 2020 Jul;34(3):100547.
   PubMedGoogle Scholar
• Cebria IIMA, Vos R, Verleden GM, et al. Evolution of functional exercise capacity in lung transplant patients with and without bronchiolitis obliterans syndrome: a longitudinal case-control study. Arch Bronconeumol. 2019 May;55(5):239–245.
   PubMed Web of Science ®Google Scholar
• Neurohr C, Huppmann P, Thum D, et al. Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis. Transpl Int. 2010 Sep;23(9):887–896.
   PubMed Web of Science ®Google Scholar
• Vos R, Vanaudenaerde BM, Verleden SE, et al. Bronchoalveolar lavage neutrophilia in acute lung allograft rejection and lymphocytic bronchiolitis. J Heart Lung Transplant. 2010 Nov;29(11):1259–1269.
   PubMed Web of Science ®Google Scholar
• Konen E, Gutierrez C, Chaparro C, et al. Bronchiolitis obliterans syndrome in lung transplant recipients: can thin-section CT findings predict disease before its clinical appearance? Radiology. 2004 May;231(2):467–473.
   PubMed Web of Science ®Google Scholar
• LaPar DJ, Burdick MD, Emaminia A, et al. Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker. Ann Thorac Surg. 2011 Aug;92(2):470–477. discussion 77.
   PubMed Web of Science ®Google Scholar
• Saini D, Weber J, Ramachandran S, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant. 2011 Jun;30(6):624–631.
   PubMed Web of Science ®Google Scholar
• Gunasekaran M, Sharma M, Hachem R, et al. Circulating exosomes with distinct properties during chronic lung allograft rejection. J Immunol. 2018 Apr 15;200(8):2535–2541.
   PubMed Web of Science ®Google Scholar
• Agbor-Enoh S, Wang Y, Tunc I, et al. Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation. EBioMedicine. 2019 Feb;40:541–553.
   PubMed Web of Science ®Google Scholar
• Yang JYC, Verleden SE, Zarinsefat A, et al. Cell-free DNA and CXCL10 derived from bronchoalveolar lavage predict lung transplant survival. J Clin Med. 2019 Feb 13;8(2). DOI:10.3390/jcm8020241.
   Web of Science ®Google Scholar
• Tissot A, Danger R, Claustre J, et al. Early identification of chronic lung allograft dysfunction: the need of biomarkers. Front Immunol. 2019;10(1681).
   PubMedGoogle Scholar
• Krishna R, Anjum F, Oliver TI. Bronchiolitis obliterans (Obliterative Bronchiolitis, Constrictive Bronchiolitis). Treasure Island (FL): StatPearls; 2020.
   Google Scholar
• Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21(3):297–310.
   PubMed Web of Science ®Google Scholar
• Gunasekaran M, Xu Z, Nayak DK, et al. Donor-derived exosomes with lung self-antigens in human lung allograft rejection. Am J Transplant. 2017 Feb;17(2):474–484.
   PubMed Web of Science ®Google Scholar
• Nayak DK, Zhou F, Xu M, et al. Zbtb7a induction in alveolar macrophages is implicated in anti-HLA-mediated lung allograft rejection. Sci Transl Med. 2017 Jul 12;9(398). DOI:10.1126/scitranslmed.aal1243.
   PubMed Web of Science ®Google Scholar
• Fukami N, Ramachandran S, Saini D, et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol. 2009 Jan 1;182(1):309–318.
   PubMed Web of Science ®Google Scholar
• Rao U, Sharma M, Mohanakumar T, et al. Prevalence of antibodies to lung self-antigens (Kalpha1 tubulin and collagen V) and donor specific antibodies to HLA in lung transplant recipients and implications for lung transplant outcomes: single center experience. Transpl Immunol. 2019 Jun;54:65–72.
   PubMed Web of Science ®Google Scholar
• Tikkanen JM, Singer LG, Kim SJ, et al. De novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2016 Sep 1;194(5):596–606.
   PubMed Web of Science ®Google Scholar
• Morrell MR, Pilewski JM, Gries CJ, et al. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant. 2014 Dec;33(12):1288–1294.
   PubMed Web of Science ®Google Scholar
• Lyu DM, Grazia TJ, Benson AB, et al. Pre-transplant presence of antibodies to MICA and HLA class I or II are associated with an earlier onset of bronchiolitis obliterans syndrome in lung transplant recipients. Clin Transpl. 2012; 237–246.
   PubMedGoogle Scholar
• Fernandez R, Chiu S, Raparia K, et al. Humoral human lung allograft rejection by tissue-restricted non-HLA antibodies. Ann Thorac Surg. 2016 Oct;102(4):e339–41.
   PubMed Web of Science ®Google Scholar
• Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg. 1995;110(1):4–13.
   PubMed Web of Science ®Google Scholar
• Keller CA, Cagle PT, Brown RW, et al. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest. 1995 Apr;107(4):973–980.
   PubMed Web of Science ®Google Scholar
• Hachem RR, Khalifah AP, Chakinala MM, et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation. 2005 Nov 27;80(10):1406–1413.
   PubMed Web of Science ®Google Scholar
• Glanville AR, Aboyoun CL, Havryk A, et al. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med. 2008 May 1;177(9):1033–1040.
   PubMed Web of Science ®Google Scholar
• Gunasekaran M, Bansal S, Ravichandran R, et al. Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection. J Heart Lung Transplant. 2020 Apr;39(4):379–388.
   PubMed Web of Science ®Google Scholar
• Martin-Gandul C, Mueller NJ, Pascual M, et al. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant. 2015 Dec;15(12):3024–3040.
   PubMed Web of Science ®Google Scholar
• Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med. 2010 Jun 15;181(12):1391–1396.
   PubMed Web of Science ®Google Scholar
• Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant. 2009 Aug;9(8):1903–1911.
   PubMed Web of Science ®Google Scholar
• Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation. 2008 Mar 15;85(5):771–774.
   PubMed Web of Science ®Google Scholar
• Bharat A, Kuo E, Steward N, et al. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg. 2008 Jul;86(1):189–195. discussion 96-7.
   PubMed Web of Science ®Google Scholar
• Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007 Mar 1;175(5):507–513.
   PubMed Web of Science ®Google Scholar
• Whitson BA, Prekker ME, Herrington CS, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant. 2007 Oct;26(10):1004–1011.
   PubMed Web of Science ®Google Scholar
• Leiva-Juarez MM, Urso A, Arango Tomas E, et al. Extended post-ex vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: results from a multicentric study. J Heart Lung Transplant. 2020 May 16. DOI:10.1016/j.healun.2020.05.002.
   PubMed Web of Science ®Google Scholar
• Shah N, Force SD, Mitchell PO, et al. Gastroesophageal reflux disease is associated with an increased rate of acute rejection in lung transplant allografts. Transplant Proc. 2010 Sep;42(7):2702–2706.
   PubMed Web of Science ®Google Scholar
• King BJ, Iyer H, Leidi AA, et al. Gastroesophageal reflux in bronchiolitis obliterans syndrome: a new perspective. J Heart Lung Transplant. 2009 Sep;28(9):870–875.
   PubMed Web of Science ®Google Scholar
• Bobadilla JL, Jankowska-Gan E, Xu Q, et al. Reflux-induced collagen type v sensitization: potential mediator of bronchiolitis obliterans syndrome. Chest. 2010 Aug;138(2):363–370.
   PubMed Web of Science ®Google Scholar
• Masuda T, Mittal SK, Kovacs B, et al. Foregut function before and after lung transplant. J Thorac Cardiovasc Surg. 2019 Aug;158(2):619–629.
   PubMed Web of Science ®Google Scholar
• D’Ovidio F, Mura M, Tsang M, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg. 2005 May;129(5):1144–1152.
   PubMed Web of Science ®Google Scholar
• Griffin SM, Robertson AG, Bredenoord AJ, et al. Aspiration and allograft injury secondary to gastroesophageal reflux occur in the immediate post-lung transplantation period (prospective clinical trial). Ann Surg. 2013 Nov;258(5):705–711. discussion 11-2.
   PubMed Web of Science ®Google Scholar
• Heng D, Sharples LD, McNeil K. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant. 1998;17:1255–1263.
   PubMed Web of Science ®Google Scholar
• Finlen Copeland CA, Snyder LD, Zaas DW, et al. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med. 2010 Sep 15;182(6):784–789.
   PubMed Web of Science ®Google Scholar
• Leuschner G, Lauseker M, Howanietz AS, et al. Longitudinal lung function measurements in single lung transplant recipients with chronic lung allograft dysfunction. J Heart Lung Transplant. 2020 Aug 26. DOI:10.1016/j.healun.2020.08.008.
   PubMedGoogle Scholar
• Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant. 2011 Sep;30(9):990–996.
   PubMed Web of Science ®Google Scholar
• Schulz U, Solidoro P, Muller V, et al. CMV Immunoglobulins for the treatment of CMV infections in thoracic transplant recipients. Transplantation. 2016 Mar;100(Suppl 3):S5–10.
   PubMed Web of Science ®Google Scholar
• Clausen ES, Zaffiri L. Infection prophylaxis and management of viral infection. Ann Transl Med. 2020 Mar;8(6):415.
   PubMed Web of Science ®Google Scholar
• Warnecke G, Van Raemdonck D, Smith MA, et al. Normothermic ex-vivo preservation with the portable organ care system lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study. Lancet Respir Med. 2018 May;6(5):357–367.
   PubMed Web of Science ®Google Scholar
• Whitford H, Walters EH, Levvey B, et al. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial. Transplantation. 2002 Jun 15;73(11):1793–1799.
   PubMed Web of Science ®Google Scholar
• Davis RD Jr., Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg. 2003 Mar;125(3):533–542.
   PubMed Web of Science ®Google Scholar
• Cantu E 3rd, Appel JZ 3rd, Hartwig MG, et al. J. Maxwell chamberlain memorial paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg. 2004 Oct;78(4):1142–1151. discussion 42–51.
   PubMed Web of Science ®Google Scholar
• Biswas Roy S, Elnahas S, Serrone R, et al. Early fundoplication is associated with slower decline in lung function after lung transplantation in patients with gastroesophageal reflux disease. J Thorac Cardiovasc Surg. 2018 Jun;155(6):2762–71 e1.
   PubMed Web of Science ®Google Scholar
• Hartwig MG, Anderson DJ, Onaitis MW, et al. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. Ann Thorac Surg. 2011 Aug;92(2):462–468. discussion; 68–9.
   PubMed Web of Science ®Google Scholar
• Gulack BC, Meza JM, Lin SS, et al. Reflux and allograft dysfunction: is there a connection? Thorac Surg Clin. 2015;25(1):97–105.
   PubMed Web of Science ®Google Scholar
• Verleden GM, Vos R, Vanaudenaerde B, et al. Current views on chronic rejection after lung transplantation. Transpl Int. 2015 Oct;28(10):1131–1139.
   PubMed Web of Science ®Google Scholar
• Davidson JR, Franklin D, Kumar S, et al. Fundoplication to preserve allograft function after lung transplant: systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2020 Sep;160(3):858–866.
   Web of Science ®Google Scholar
• Cairn J, Yek T, Banner NR, et al. Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2003 Jan;22(1):50–57.
   PubMed Web of Science ®Google Scholar
• Whyte RI, Rossi SJ, Mulligan MS, et al. Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. Ann Thorac Surg. 1997 Oct;64(4):945–948.
   PubMed Web of Science ®Google Scholar
• Roman A, Bravo C, Monforte V, et al. Preliminary results of rescue therapy with tacrolimus and mycophenolate mofetil in lung transplanted patients with bronchiolitis obliterans. Transplant Proc. 2002 Feb;34(1):146–147.
   PubMed Web of Science ®Google Scholar
• Revell MP, Lewis ME, Llewellyn-Jones CG, et al. Conservation of small-airway function by tacrolimus/cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation. J Heart Lung Transplant. 2000 Dec;19(12):1219–1223.
   PubMed Web of Science ®Google Scholar
• Verleden GM, Dupont LJ, Van Raemdonck D, et al. Effect of switching from cyclosporine to tacrolimus on exhaled nitric oxide and pulmonary function in patients with chronic rejection after lung transplantation. J Heart Lung Transplant. 2003 Aug;22(8):908–913.
   PubMed Web of Science ®Google Scholar
• Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004 May 15;77(9):1465–1467.
   PubMed Web of Science ®Google Scholar
• Yates B, Murphy DM, Forrest IA, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2005 Sep 15;172(6):772–775.
   PubMed Web of Science ®Google Scholar
• Shitrit D, Bendayan D, Gidon S, et al. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant. 2005 Sep;24(9):1440–1443.
   PubMed Web of Science ®Google Scholar
• Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J. 2011 Jan;37(1):164–172.
   PubMed Web of Science ®Google Scholar
• Gan CT, Ward C, Meachery G, et al. Long-term effect of azithromycin in bronchiolitis obliterans syndrome. BMJ Open Respir Res. 2019;6(1):e000465.
   PubMed Web of Science ®Google Scholar
• Ruttens D, Verleden SE, Vandermeulen E, et al. Prophylactic azithromycin therapy after lung transplantation: post hoc analysis of a randomized controlled trial. Am J Transplant. 2016 Jan;16(1):254–261.
   PubMed Web of Science ®Google Scholar
• li D, Duan Q, Weinkauf J, et al. Azithromycin prophylaxis after lung transplant is associated with improved overall survival. J Heart Lung Transplant. 2020. DOI:10.1016/j.healun.2020.09.006.
   Google Scholar
• Szczepanik A, Hulbert A, Lee HJ, et al. Effect of HMG CoA reductase inhibitors on the development of chronic lung allograft dysfunction. Clin Transplant. 2018 Jan 32:1.
   Web of Science ®Google Scholar
• Verleden GM, Verleden SE, Vos R, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transpl Int. 2011 Jul;24(7):651–656.
   PubMed Web of Science ®Google Scholar
• Ruttens D, Verleden SE, Demeyer H, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a randomized controlled trial. PLoS One. 2018;13(4):e0193564.
   PubMed Web of Science ®Google Scholar
• Vos R, Eynde RV, Ruttens D, et al. Montelukast in chronic lung allograft dysfunction after lung transplantation.. J Heart Lung Transplant. 2019 May;38(5):516–527.
   PubMed Web of Science ®Google Scholar
• Moes DJ, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 2015 Oct;20(10):1243–1249.
   PubMed Web of Science ®Google Scholar
• Roman A, Ussetti P, Zurbano F, et al. A retrospective 12-month study of conversion to everolimus in lung transplant recipients. Transplant Proc. 2011 Sep;43(7):2693–2698.
   PubMed Web of Science ®Google Scholar
• Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant. 2004 May;23(5):632–638.
   PubMed Web of Science ®Google Scholar
• Wojarski J, Zeglen S, Ochman M, et al. Early sirolimus-based immunosuppression is safe for lung transplantation patients: retrospective, single arm, exploratory study. Ann Transplant. 2018 Aug;23(23):598–607.
   PubMedGoogle Scholar
• Fisher AJ, Rutherford RM, Bozzino J, et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2005 Mar;5(3):537–543.
   PubMed Web of Science ®Google Scholar
• Verleden GM, Lievens Y, Dupont LJ, et al. Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation. Transplant Proc. 2009 Jun;41(5):1816–1820.
   PubMed Web of Science ®Google Scholar
• Lebeer M, Kaes J, Lambrech M, et al. Total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation: a single-center experience and review of literature. Transpl Int. 2020 Feb;33(2):216–228.
   PubMed Web of Science ®Google Scholar
• Xia CQ, Campbell KA, Clare-Salzler MJ. Extracorporeal photopheresis-induced immune tolerance: a focus on modulation of antigen-presenting cells and induction of regulatory T cells by apoptotic cells. Curr Opin Organ Transplant. 2009 Aug;14(4):338–343.
   PubMed Web of Science ®Google Scholar
• Benden C, Speich R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation. 2008 Dec 15;86(11):1625–1627.
   PubMed Web of Science ®Google Scholar
• Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2010 Apr;29(4):424–431.
   PubMed Web of Science ®Google Scholar
• Jaksch P, Scheed A, Keplinger M, et al. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2012 Sep;31(9):950–957.
   PubMed Web of Science ®Google Scholar
• Del Fante C, Scudeller L, Oggionni T, et al. Long-term off-line extracorporeal photochemotherapy in patients with chronic lung allograft rejection not responsive to conventional treatment: a 10-year single-centre analysis. Respiration. 2015;90(2):118–128.
   PubMed Web of Science ®Google Scholar
• Baskaran G, Tiriveedhi V, Ramachandran S, et al. Efficacy of extracorporeal photopheresis in clearance of antibodies to donor-specific and lung-specific antigens in lung transplant recipients. J Heart Lung Transplant. 2014 Sep;33(9):950–956.
   PubMed Web of Science ®Google Scholar
• Karnes HE, Schindler EI, Morrell M, et al. Factors associated with mortality and response to extracorporeal photopheresis in lung allograft recipients with bronchiolitis obliterans syndrome. Transplantation. 2019 May;103(5):1036–1042.
   PubMed Web of Science ®Google Scholar
• Biswas Roy S, Panchanathan R, Walia R, et al. Lung retransplantation for chronic rejection: a single-center experience. Ann Thorac Surg. 2018 Jan;105(1):221–227.
   PubMed Web of Science ®Google Scholar
• Verleden SE, Todd JL, Sato M, et al. Impact of CLAD phenotype on survival after lung retransplantation: a multicenter study. Am J Transplant. 2015 Aug;15(8):2223–2230.
   PubMed Web of Science ®Google Scholar
• Mohanakumar T, Sharma M, Bansal S, et al. A novel mechanism for immune regulation after human lung transplantation. J Thorac Cardiovasc Surg. 2019 May;157(5):2096–2106.
   PubMed Web of Science ®Google Scholar
• Sureshbabu A, Fleming T, Mohanakumar T. Autoantibodies in lung transplantation. Transpl Int. 2020 Jan;33(1):41–49.
   PubMed Web of Science ®Google Scholar
• Rahman M, Sureshbabu A, Tokman S, et al. Chronic lung allograft dysfunction: immune responses induced by circulating exosomes with lung-associated self-antigens. Crit Rev Immunol. 2019;39(2):123–134.
   PubMed Web of Science ®Google Scholar
• Bansal S, McGilvrey M, Garcia-Mansfield K, et al. Global proteomics analysis of circulating extracellular vesicles isolated from lung transplant recipients. ACS Omega. 2020 Jun 23;5(24):14360–14369.
   PubMed Web of Science ®Google Scholar
• Sharma M, Gunasekaran M, Ravichandran R, et al. Circulating exosomes with lung self-antigens as a biomarker for chronic lung allograft dysfunction: a retrospective analysis. J Heart Lung Transplant. 2020 In press. DOI: 10.1016/j.healun.2020.07.001.
   Web of Science ®Google Scholar
• Zhang R, Fang H, Chen R, et al. IL-17A is critical for CD8+ T effector response in airway epithelial injury after transplantation. Transplantation. 2018 Dec;102(12):e483–e93.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Ammerman N, Choi J, et al. Interleukin 6: an important mediator of allograft injury. Transplantation. 2020 Mar 30. DOI:10.1097/TP.0000000000003249.
   Web of Science ®Google Scholar